Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
  2. c-icon icon-chevron-right
August 12, 2013

Nuevolution enters scientific partnership with Duke University, Howard Hughes, Lexicon

Small molecule lead discovery company Nuevolution has partnered with Duke University, the Howard Hughes Medical Institute, and Lexicon Pharmaceuticals, to evaluate the biological mechanism of action of a specified GPCR drug target.

Small molecule lead discovery company Nuevolution has partnered with Duke University, the Howard Hughes Medical Institute and Lexicon Pharmaceuticals, to evaluate the biological mechanism of action of a specified GPCR drug target.

The scientific collaboration will leverage Nuevolution’s proprietary Chemetics technology for small molecule drug discovery.

Both Nuevolution and Lexicon will provide access to selected chemical libraries created using the Chemetics technology.

"If successful, the project could provide a new level of understanding on the mechanism of action of GPCRs."

Nuevolution chief scientific officer Thomas Franch said under the scientific collaboration the company looks forward to working with the scientific group of Dr Lefkowitz and its partner Lexicon Pharmaceuticals.

Under the collaboration, several diverse small molecules will be screened in an attempt to discover compounds with certain novel and unique properties against the GPCR drug target.

If successful, the project could provide a new level of understanding on the mechanism of action of GPCRs, according to Nuevolution.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Lexicon executive vice-president and chief scientific officer Dr Brian Zambrowicz said the Chemetics technology was successfully used to identify novel chemotypes for internal programs.

The company will now explore the use of its DNA-tagged libraries of diverse chemical compounds in the screening of GPCRs, according to Zambrowicz.

"We look forward to working with Nuevolution and Dr. Lefkowitz’s team at Duke University on this project," Zambrowicz said.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU